Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2009

View Archived Issues

An exploratory memantine trial in amyotrophic lateral sclerosis produces discouraging results

KNS-760704 is well tolerated and may be beneficial in treating amyotrophic lateral sclerosis

Recent studies of dengue vaccines presented at the ASTMH meeting

NanoPacific Holdings acquires license from UCLA for supramolecular nanoparticles

CSL and Sanofi Pasteur are developing vaccine to treat gum disease

Sanofi Pasteur expands global clinical program of its dengue vaccine

GSK initiates second pivotal phase III trial of darapladib

QLT reports results of EVEREST trial of Visudyne(R) in polypoidal choroidal vasculopathy

Repligen reports phase III trial results of RG-1068 in pancreatic imaging

Targacept initiates phase II proof-of-concept trial of TC-5619 in schizophrenia

Algeta initiates phase III ALSYMPCA trial of Alpharadin in CRPC in the U.S.

GSK and Intercell collaborate to develop needle-free, patch-based vaccines

Daiichi reports on phase III trial of edoxaban to prevent postoperative venous thromboembolism

Johnson & Johnson reports results from phase III trial of Invega Sustenna in schizophrenia

AstraZeneca describes TAK1 inhibitor with potential for treating mantle cell lymphoma

Basilea's Toctino recommended for approval for hand eczema in additional E.U. countries

NDDPX-08 increases survival and delays disease progression in mouse model of ALS

European Commission grants marketing authorization to Pfizer's Prevenar 13 vaccine

MediGene presents update on clinical development of EndoTAG-1 and RhuDex

University of California, Oakland discloses neuraminidase inhibitors for avian influenza

Arpida completes merger with Evolva

Novartis presents novel ALK inhibitors for treatment of pulmonary hypertension

Takeda identifies novel kinase inhibitors for the treatment of cancer

Aztreonam for inhalation solution recommended for approval by FDA advisory committee

Cubist Pharmaceuticals to acquire Calixa Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....